Literature DB >> 28457178

Postoperative Outcomes in Graves' Disease Patients: Results from the Nationwide Inpatient Sample Database.

Gustavo A Rubio1, Tulay Koru-Sengul2,3, Tanaz M Vaghaiwalla1, Punam P Parikh1, Josefina C Farra1,3, John I Lew1,3.   

Abstract

BACKGROUND: Current surgical indications for Graves' disease include intractability to medical and/or radioablative therapy, compressive symptoms, and worsening ophthalmopathy. Total thyroidectomy for Graves' disease may be technically challenging and lead to untoward perioperative outcomes. This study examines outcomes in patients with Graves' disease who underwent total thyroidectomy and assesses its safety for this patient population.
METHODS: A retrospective cross-sectional analysis was performed using the Nationwide Inpatient Sample database from 2006 to 2011. Total thyroidectomy performed in patients with Graves' disease, benign multinodular goiter (MNG), and thyroid cancer was identified. Demographic factors, comorbidities, and postoperative complications were evaluated. Chi-square, one-way analysis of variance, and risk-adjusted multivariable logistic regression were performed.
RESULTS: Of 215,068 patients who underwent total thyroidectomy during the study period, 11,205 (5.2%) had Graves' disease, 110,124 (51.2%) MNG, and 93,739 (43.6%) thyroid malignancy. Patients with Graves' disease were younger than MNG and thyroid cancer patients (Mage = 42.8 years vs. 55.5 and 51.0 years; p < 0.01). The Graves' disease group included a higher proportion of women (p < 0.01) and nonwhites (p < 0.01). Postoperatively, Graves' patients had significantly higher rates of hypocalcemia (12.4% vs. 7.3% and 10.3%; p < 0.01), hematomas requiring reoperation (0.7% vs. 0.4% and 0.4%; p < 0.01), and longer mean hospital stay (2.7 days vs. 2.4 and 2.2 days; p < 0.01) compared to MNG and thyroid cancer patients, respectively. On risk-adjusted multivariate logistic regression, Graves' disease was independently associated with a higher risk of vocal-cord paralysis (odds ratio [OR] = 1.36 [confidence interval (CI) 1.08-1.69]), tracheostomy (OR = 1.35 [CI 1.1-1.67]), postoperative hypocalcemia (OR = 1.65 [CI 1.54-1.77]), and hematoma requiring reoperation (OR = 2.79 [CI 2.16-3.62]) compared to MNG patients. High-volume centers for total thyroidectomy were independently associated with lower risk of postoperative complications, including in patients with Graves' disease.
CONCLUSIONS: Despite low overall morbidity following total thyroidectomy, Graves' disease patients are at increased risk of postoperative complications, including bleeding, vocal-cord paralysis, tracheostomy, and hypocalcemia. These risks appear to be lower when performed at high-volume centers, and thus referral to these centers should be considered. Total thyroidectomy may therefore be a safe treatment option for appropriately selected patients with Graves' disease when performed by experienced surgeons.

Entities:  

Keywords:  complications; hematoma; hypocalcemia; outcomes; safety; thyroidectomy

Mesh:

Year:  2017        PMID: 28457178     DOI: 10.1089/thy.2016.0500

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  9 in total

1.  Outcomes After Urgent Thyroidectomy Following Rapid Control of Thyrotoxicosis in Graves' Disease are Similar to Those After Elective Surgery in Well-Controlled Disease.

Authors:  Adibah Ali; Miguel Debono; Sabapathy P Balasubramanian
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

2.  Association of Surgical Volume and Quality Management in Thyroid Surgery: A Two-Nation Multicenter Study.

Authors:  Dominik A Jakob; Philipp Riss; Christian Scheuba; Michael Hermann; Corina Kim-Fuchs; Christian A Seiler; Martin A Walter; Reto M Kaderli
Journal:  World J Surg       Date:  2019-09       Impact factor: 3.352

3.  Can we still consider thyroid hyperfunction a protective condition for the onset of thyroid cancer?

Authors:  Elena Bonati; Stefania Bettoni; Tommaso Loderer; Paolo Del Rio
Journal:  Gland Surg       Date:  2021-04

Review 4.  Volume, outcomes, and quality standards in thyroid surgery: an evidence-based analysis-European Society of Endocrine Surgeons (ESES) positional statement.

Authors:  Kerstin Lorenz; Marco Raffaeli; Marcin Barczyński; Leyre Lorente-Poch; Joan Sancho
Journal:  Langenbecks Arch Surg       Date:  2020-06-10       Impact factor: 3.445

5.  Short-Term Outcomes of Surgery for Graves' Disease in Germany.

Authors:  Elisabeth Maurer; Christian Vorländer; Andreas Zielke; Cornelia Dotzenrath; Moritz von Frankenberg; Hinrich Köhler; Kerstin Lorenz; Theresia Weber; Joachim Jähne; Antonia Hammer; Knut A Böttcher; Katharina Schwarz; Carsten Klinger; Heinz J Buhr; Detlef K Bartsch
Journal:  J Clin Med       Date:  2020-12-11       Impact factor: 4.241

6.  Accumulation of Experience and Newly Developed Devices Can Improve the Safety and Voice Outcome of Total Thyroidectomy for Graves' Disease.

Authors:  Cheng-Hsun Chuang; Tzu-Yen Huang; Tzer-Zen Hwang; Che-Wei Wu; I-Cheng Lu; Pi-Ying Chang; Yi-Chu Lin; Ling-Feng Wang; Chih-Chun Wang; Ching-Feng Lien; Gianlorenzo Dionigi; Chih-Feng Tai; Feng-Yu Chiang
Journal:  J Clin Med       Date:  2022-02-27       Impact factor: 4.241

7.  Clinical and Anatomical Factors Affecting Recurrent Laryngeal Nerve Paralysis During Thyroidectomy via Intraoperative Nerve Monitorization.

Authors:  Nurcihan Aygun; Mehmet Kostek; Mehmet Taner Unlu; Adnan Isgor; Mehmet Uludag
Journal:  Front Surg       Date:  2022-04-28

8.  Frequency of thyroid nodules and thyroid cancer in thyroidectomized patients with Graves' disease.

Authors:  Caglar Keskin; Mustafa Sahin; Rovshan Hasanov; Berna Imge Aydogan; Ozgur Demir; Rıfat Emral; Sevim Gullu; Murat Faik Erdogan; Vedia Gedik; Ali Riza Uysal; Nilgun Baskal; Demet Corapcioglu
Journal:  Arch Med Sci       Date:  2019-01-11       Impact factor: 3.318

9.  Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience.

Authors:  Anupam Kotwal; Jennifer Clark; Melanie Lyden; Travis McKenzie; Geoffrey Thompson; Marius N Stan
Journal:  J Endocr Soc       Date:  2018-09-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.